GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003253515 | Cervix | HSIL_HPV | regulation of cellular component size | 27/737 | 383/18723 | 2.63e-03 | 2.54e-02 | 27 |
GO:009758112 | Cervix | HSIL_HPV | lamellipodium organization | 10/737 | 90/18723 | 2.81e-03 | 2.66e-02 | 10 |
GO:004586013 | Cervix | HSIL_HPV | positive regulation of protein kinase activity | 27/737 | 386/18723 | 2.93e-03 | 2.74e-02 | 27 |
GO:000806413 | Cervix | HSIL_HPV | regulation of actin polymerization or depolymerization | 16/737 | 188/18723 | 3.18e-03 | 2.89e-02 | 16 |
GO:003083213 | Cervix | HSIL_HPV | regulation of actin filament length | 16/737 | 189/18723 | 3.35e-03 | 3.03e-02 | 16 |
GO:003210322 | Cervix | N_HPV | positive regulation of response to external stimulus | 33/534 | 427/18723 | 2.38e-07 | 1.84e-05 | 33 |
GO:190290325 | Cervix | N_HPV | regulation of supramolecular fiber organization | 27/534 | 383/18723 | 1.61e-05 | 4.86e-04 | 27 |
GO:002261325 | Cervix | N_HPV | ribonucleoprotein complex biogenesis | 30/534 | 463/18723 | 2.78e-05 | 7.49e-04 | 30 |
GO:000701525 | Cervix | N_HPV | actin filament organization | 29/534 | 442/18723 | 3.00e-05 | 8.02e-04 | 29 |
GO:003297025 | Cervix | N_HPV | regulation of actin filament-based process | 27/534 | 397/18723 | 3.03e-05 | 8.02e-04 | 27 |
GO:000225321 | Cervix | N_HPV | activation of immune response | 26/534 | 375/18723 | 3.06e-05 | 8.02e-04 | 26 |
GO:004227425 | Cervix | N_HPV | ribosomal small subunit biogenesis | 10/534 | 73/18723 | 4.05e-05 | 9.70e-04 | 10 |
GO:004225424 | Cervix | N_HPV | ribosome biogenesis | 21/534 | 299/18723 | 1.46e-04 | 2.68e-03 | 21 |
GO:003134921 | Cervix | N_HPV | positive regulation of defense response | 20/534 | 278/18723 | 1.51e-04 | 2.77e-03 | 20 |
GO:000002825 | Cervix | N_HPV | ribosomal small subunit assembly | 5/534 | 19/18723 | 1.55e-04 | 2.77e-03 | 5 |
GO:004325425 | Cervix | N_HPV | regulation of protein-containing complex assembly | 26/534 | 428/18723 | 2.62e-04 | 4.15e-03 | 26 |
GO:006184212 | Cervix | N_HPV | microtubule organizing center localization | 6/534 | 33/18723 | 3.01e-04 | 4.64e-03 | 6 |
GO:003295625 | Cervix | N_HPV | regulation of actin cytoskeleton organization | 22/534 | 358/18723 | 6.55e-04 | 8.42e-03 | 22 |
GO:005125824 | Cervix | N_HPV | protein polymerization | 19/534 | 297/18723 | 9.32e-04 | 1.11e-02 | 19 |
GO:199082312 | Cervix | N_HPV | response to leukemia inhibitory factor | 9/534 | 95/18723 | 1.56e-03 | 1.63e-02 | 9 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0517114 | Liver | NAFLD | Coronavirus disease - COVID-19 | 111/1043 | 232/8465 | 1.01e-41 | 3.32e-39 | 2.67e-39 | 111 |
hsa04610 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa0481010 | Liver | NAFLD | Regulation of actin cytoskeleton | 50/1043 | 229/8465 | 3.01e-05 | 7.59e-04 | 6.11e-04 | 50 |
hsa0517115 | Liver | NAFLD | Coronavirus disease - COVID-19 | 111/1043 | 232/8465 | 1.01e-41 | 3.32e-39 | 2.67e-39 | 111 |
hsa046101 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa0481011 | Liver | NAFLD | Regulation of actin cytoskeleton | 50/1043 | 229/8465 | 3.01e-05 | 7.59e-04 | 6.11e-04 | 50 |
hsa0517122 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa0502014 | Liver | Cirrhotic | Prion disease | 152/2530 | 273/8465 | 1.84e-19 | 8.78e-18 | 5.41e-18 | 152 |
hsa046102 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0481021 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa05133 | Liver | Cirrhotic | Pertussis | 37/2530 | 76/8465 | 4.17e-04 | 2.57e-03 | 1.58e-03 | 37 |
hsa04936 | Liver | Cirrhotic | Alcoholic liver disease | 60/2530 | 142/8465 | 1.07e-03 | 5.85e-03 | 3.61e-03 | 60 |
hsa0517132 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa0502015 | Liver | Cirrhotic | Prion disease | 152/2530 | 273/8465 | 1.84e-19 | 8.78e-18 | 5.41e-18 | 152 |
hsa046103 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0481031 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa051331 | Liver | Cirrhotic | Pertussis | 37/2530 | 76/8465 | 4.17e-04 | 2.57e-03 | 1.58e-03 | 37 |
hsa049361 | Liver | Cirrhotic | Alcoholic liver disease | 60/2530 | 142/8465 | 1.07e-03 | 5.85e-03 | 3.61e-03 | 60 |
hsa0502022 | Liver | HCC | Prion disease | 195/4020 | 273/8465 | 3.26e-16 | 1.56e-14 | 8.67e-15 | 195 |
hsa0517142 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
C5 | SNV | Missense_Mutation | | c.4015G>C | p.Glu1339Gln | p.E1339Q | P01031 | protein_coding | tolerated(0.2) | probably_damaging(0.946) | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
C5 | SNV | Missense_Mutation | | c.759N>T | p.Arg253Ser | p.R253S | P01031 | protein_coding | tolerated(0.5) | benign(0.003) | TCGA-A2-A25E-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD |
C5 | SNV | Missense_Mutation | | c.2762N>G | p.Glu921Gly | p.E921G | P01031 | protein_coding | deleterious(0) | possibly_damaging(0.655) | TCGA-A8-A07L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | | CR |
C5 | SNV | Missense_Mutation | rs758293412 | c.3422G>A | p.Ser1141Asn | p.S1141N | P01031 | protein_coding | deleterious(0.04) | benign(0.003) | TCGA-A8-A097-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
C5 | SNV | Missense_Mutation | | c.1086N>A | p.Phe362Leu | p.F362L | P01031 | protein_coding | deleterious(0) | possibly_damaging(0.73) | TCGA-A8-A09G-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
C5 | SNV | Missense_Mutation | | c.1118T>C | p.Val373Ala | p.V373A | P01031 | protein_coding | tolerated(0.08) | benign(0.007) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C5 | SNV | Missense_Mutation | novel | c.4517N>T | p.Thr1506Ile | p.T1506I | P01031 | protein_coding | deleterious(0.03) | probably_damaging(0.992) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C5 | SNV | Missense_Mutation | rs369245774 | c.2017N>A | p.Leu673Ile | p.L673I | P01031 | protein_coding | tolerated(0.08) | benign(0.003) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C5 | SNV | Missense_Mutation | novel | c.711N>A | p.Phe237Leu | p.F237L | P01031 | protein_coding | deleterious(0.01) | possibly_damaging(0.6) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C5 | SNV | Missense_Mutation | novel | c.1643N>A | p.Gly548Glu | p.G548E | P01031 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
727 | C5 | PROTEASE INHIBITOR, DRUGGABLE GENOME, ENZYME | | eculizumab | ECULIZUMAB | 24521109 |
727 | C5 | PROTEASE INHIBITOR, DRUGGABLE GENOME, ENZYME | | LFG-316 | TESIDOLUMAB | 24860651 |
727 | C5 | PROTEASE INHIBITOR, DRUGGABLE GENOME, ENZYME | | IFX-1 | | |
727 | C5 | PROTEASE INHIBITOR, DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL1201828 | ECULIZUMAB | |
727 | C5 | PROTEASE INHIBITOR, DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL2107979 | PEXELIZUMAB | |
727 | C5 | PROTEASE INHIBITOR, DRUGGABLE GENOME, ENZYME | | SAND-5 | | 22990692 |
727 | C5 | PROTEASE INHIBITOR, DRUGGABLE GENOME, ENZYME | | Ravulizumab | RAVULIZUMAB | |
727 | C5 | PROTEASE INHIBITOR, DRUGGABLE GENOME, ENZYME | | NNC-0151-0000-0000 | | |
727 | C5 | PROTEASE INHIBITOR, DRUGGABLE GENOME, ENZYME | | ECULIZUMAB | ECULIZUMAB | |
727 | C5 | PROTEASE INHIBITOR, DRUGGABLE GENOME, ENZYME | | ARC-1905 | AVACINCAPTAD PEGOL SODIUM | |